Reference - Detail
|Author||Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T.|
|Title||Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.|
|Journal||J Pediatr Surg|
PURPOSE:In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma. However, what kind of effector cells for the combined therapy were used to show the antitumor effect was unclear. In this study, we performed radiation and rSeV/DC therapy in vivo and examined the effector cells involved.
METHODS:Dendritic cells were cultured from bone marrow cells, activated with SeV and administered intratumorally at 106 weekly for 3weeks. Radiation was administered at 4Gy/time × 3 times. During the treatment, CD4+ and CD8+ cells and natural killer (NK) cells were removed by antibodies.
RESULTS:Complete remission of neuroblastoma was observed in 62.5% of individuals in the combined therapy group. By depleting the effector cells using antibodies, the tumor increased in size from an early stage of treatment in the CD4+ and NK cell-depleted group. In contrast, the tumor increased in size in the late stage of treatment in the CD8+ cell-depleted group.
CONCLUSION:The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment.
LEVEL OF EVIDENCE:V.
|MeSH||Animals Bone Marrow Cells / pathology Dendritic Cells / immunology* Humans Killer Cells, Natural Lymphocyte Activation / immunology* Mice Neuroblastoma / immunology* Neuroblastoma / pathology Sendai virus Virus Activation / immunology*|
|Human and Animal Cells||C-1300(RCB0283) MuSS(RCB1378)|